Bayer AG surges 4% in pre-market on possible out-of-court glyphosate settlement


by   |  VIEW 851
Bayer AG surges 4% in pre-market on possible out-of-court glyphosate settlement

On Friday, the 24th of January 2020, shares’ prices of Leverkusen-based German multinational life sciences and pharmaceutical company, Bayer AG climbed as much as 4 per cent in pre-market trading to €76.74 a share, its highest level since October 2018, following reveal of a report that the seeds and pesticide maker, Bayer, might snatch a window of opportunity of a possible out-of-the-court settlement over a US trial accusing its glyphosate-containing weedkiller Roundup to cause cancers in human.

In point of fact, It has been more than a year and a half now the German pharmaceutical had received an approval for its $66 billion Monsanto takeover from the US anti-trust watchdog though the German firm had been little aware of the potential charges related to its purchase of US-based pesticide maker Monsanto, the manufacturer of Roundup weedkiller that 42,700 farmers claimed caused cancers and asked for liabilities.

Nonetheless, as a recent development of Bayer AG’s Monsanto Roundup weedkiller came in to the light, a Bloomberg report published late on Thursday (January 23rd) had first revealed some lawyers alongside US plaintiffs had been looking to an out-of-court settlement that might cost the German life science company a lump-sum of $10 billion.

Meanwhile, addressing that the market likes the concept of an out-of-court settlement, a trader said on Friday (January 24th), “It would get rid of the problem in one go,” as the pesticide manufacturer rounded off the day 1.55 per cent to €75.25 after some profit taking at after-market trading.